SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Schedule of Subsidiaries

The following table depicts the identity of the Company’s subsidiaries:

			Attributable
	Place of		Equity
Name of Subsidiary	Incorporation		Interest %
America Great Health in California		USA		100
GOF Biotechnologies in California		USA		75
International Institute of Great Health in California		USA		100
Nutrature Health LLC in California		USA		100
Sijinsai in China		CHINA		60
US-China Mega Beauty Health Industry Development Co., LTD		CHINA		100
Peptide Life Inc in California		USA		100

Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount

Below is a table with foreign exchange rates used for translation:

	March 31,
	2025
Average Nine Months (average rate)
Chinese Renminbi (RMB)	RMB	7.2097
United States dollar ($)	$	1.00

	March 31,
	2025
Nine Months Ended (Closing rate)
Chinese Renminbi (RMB)	RMB	7.2633
United States dollar ($)	$	1.00

Schedule of Consolidated Statement of Cash Flows

Consolidated Statement of Cash Flows

	Reclassified 10-Q			Original 10-Q
	March 31, 2024			March 31, 2024
Cash Flows from Operating Activities
Adjustments to reconcile net loss to net cash used in operating activities
Payment of lease and rent	$	(50,793	)	$	-
Original issue discount on debt		-			126,981
Stock based compensation		-			44,601
Changes in operating assets and liabilities
Right to use asset – net		38,412			-
Lease liabilities – net		(30,654	)		-
Account payable and accrued expense		40,254			(2,781	)
Accrued interest for short term loan		104,751			62,201
Wage and wage tax payable		(9,940	)		1,219
Other payable		6,820			(3,572	)
Income tax payable		766			-
Net cash used in operating activities from continuing operations		(450,200	)		(321,167	)
Cash Flows from Financing Activities
Proceeds from issuance of common stock		286,582			115,000
Proceeds of short term loan		37,475			25,000
Repayment of short term loan		(28,332	)		(23,966	)
Interest payment of short term loan		(55,025	)		(4,366	)
Net cash provided by financing activities		447,486			318,454
Effect of exchange rate change on cash		303			302

Schedule of Condensed Consolidated Statement of Shareholders’ Deficit

Condensed Consolidated Statement of Shareholders’ Deficit

	Preferred Stock			Common Stock				Treasury Stock				Non- Controlling			Total Shareholders’
	Shares	Amount		Shares		Amount		Shares		Amount		Interest			Deficit
Balance March 31, 2024
Reclassified 10-Q		$	-		21,136,888,326	$	-		52,100,000	$	-	$	(78,308	)	$	(4,718,783	)
Original 10-Q		$	-		21,188,988,326	$	-		-	$	-	$	(78,309	)	$	(4,873,784	)

Schedule of Inventories

As of the nine months ended on March 31 2025 and the year ended June 30, 2024, inventories comprised:

	March 31, 2025			June 30, 2024
Raw materials	$	65,177		$	56,435
Finished goods		51,579			36,106
Inventory valuation reserve		(9,400	)		(9,400	)
Subtotal	$	107,356		$	83,141

Schedule of Property and Equipment

Machinery and equipment 5 years

	March 31, 2025			June 30, 2024
Machinery and equipment	$	73,943		$	73,943
Accumulated depreciation		(42,131	)		(31,040	)
Subtotal	$	31,812		$	42,903